Chong Kun Dang’s CKD-339 Enters Phase 3 in South Korea for Patients Uncontrolled on Monotherapy
CKD-339, an essential hypertension treatment under development by Chong Kun Dang, is advancing into a Phase 3 clinical trial in South Korea.
Search results for "patient safety"
From Twin Risks to Tylenol Safety: Medical Society Addresses Four Major Pregnancy Concerns
How much does risk escalate during a twin pregnancy. Is cerebral palsy strictly caused by complications during labor and delivery.
Eyes on the Ward: AI Now Tracks General Bed Patients 24/7
The most anxious moments for hospitalized patients and their caregivers often occur when medical staff leave the room.
Unseen Safeguards: How the Modern Operating Room Protects Patients Under Anesthesia
Most hospital patients never see the inner workings of an operating room. Kept strictly behind closed doors, it is a...
Daewoong Pharmaceutical Nears Completion of Phase 2 IPF Trial for Bersiporosin, Readout Set for H1 2027
Daewoong Pharmaceutical has completed patient enrollment for the global Phase 2 clinical trial of bersiporosin...
GC Cell Administers Experimental CAR-NK Therapy at Seoul National University Hospital Following MFDS Approval
GC Cell announced on Sept. 18 that South Korea’s Ministry of Food and Drug Safety has approved the compassionate use of...
Asan Medical Center Ranks Six Specialties in World’s Top 10 in Newsweek 2027 Evaluation, Led by No. 2 Endocrinology
Asan Medical Center placed six specialties in the global top 10 of Newsweek’s “World’s Best Specialized Hospitals 2027”...
Medytox’s Cholic Acid Fat-Reduction Injectable Nuviju Surpasses 30,000 Vials in Cumulative Supply
Medytox announced on Sept. 18 that cumulative supply of Nuviju , the world’s first fat-reduction injectable formulated...
Early Flu Outbreak Shifts Demand to Ibuprofen-Based Cold Remedies as Hanmi Leads Market
With wide daily temperature fluctuations causing seasonal influenza to spread nearly a month earlier than usual in...
Yuhan Outlines Clinical Progress for Oral Targeted Anticancer Candidate YH42946 at WCLC 2026
Yuhan Corporation has detailed the status and trial design of the ongoing Phase 1/2 clinical study for YH42946, an oral...